Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Pediatric Hepatology

Building Your Care Team and Preparing for Visits

At a Glance

Children with CBAS5 benefit from coordinated care from pediatric liver, metabolic genetics, nutrition, and other specialists. Families can make visits more productive by bringing complete ABCD3 genetic results, bile acid testing, liver trends, growth records, and supplement details.

Managing an ultra-rare condition like congenital bile acid synthesis defect 5 (CBAS5) requires a specialized “home” within the medical system. Because most local pediatricians will not have seen a child with ABCD3 mutations, you will need to assemble a multidisciplinary team that can translate the complex biology of this disease into a daily care plan [1][2].

Your Core Specialized Team

A comprehensive care team for CBAS5 typically includes several key specialists working in coordination:

  • Pediatric Hepatologist (Liver Specialist): This doctor oversees your child’s liver health, monitors for signs of scarring (fibrosis), and manages the prescription and monitoring of bile acid replacement therapy, such as cholic acid [3][4].
  • Metabolic or Biochemical Geneticist: This specialist is essential for confirming that the genetic results (the ABCD3 variants) match the biochemical evidence (the levels of THCA and DHCA) [1][5].
  • Genetic Counselor: Helps you interpret complex genetic reports, explains the inheritance pattern, and guides discussions about parental testing. Note: A lab report on the child alone may not establish if the variants are in trans (one from each parent); parental testing is often needed.
  • Pediatric Dietitian: Because your child cannot absorb fats and vitamins normally, a dietitian is a critical partner. They will track growth trajectories and help adjust prescribed vitamin supplements based on regular blood tests [6][7].
  • Clinical Pharmacist: Can assist with the dosing and safety monitoring of specialized formulations.

Vetting Your Medical Team

When you meet a new specialist, it is important to understand their level of comfort with ultra-rare metabolic liver diseases. You might ask if the team has experience interpreting LC-MS (liquid chromatography–mass spectrometry) profiles for bile acid intermediates, or if they have managed other children with peroxisomal disorders or bile acid synthesis defects [7][8].

A knowledgeable team should be able to explain how they will use markers like GGT and total serum bile acids—which may be “misleadingly” normal in CBAS5—to guide treatment decisions [8][9]. They should also have a clear plan for when to refer a patient to a transplant center if medical therapy is not sufficient [10].

Preparing for the First Consultation

To make the most of your first visit with a specialist, you should bring the following “artifacts” or records. Having the original reports is more helpful than a summary from another doctor:

  1. The Full Genetic Testing Report: This should include the specific ABCD3 variants identified, their classification, and whether they were inherited from both parents [11].
  2. Specialized Bile Acid Labs: If a serum or urine LC-MS was performed, bring the report showing the exact values for THCA and DHCA [11].
  3. Liver Panel History: A chronological list or copies of tests for bilirubin, GGT, AST/ALT, and albumin help the doctor see the “trend” of the disease over time [9][12].
  4. Growth and Feeding Records: Bring data on your child’s recent weight and height measurements, along with a list of all current supplements and their exact dosages [7][13].

By arriving with these documents and a clear set of questions, you help ensure that your child’s team has everything they need to provide the most accurate and personalized care possible.

Common questions in this guide

Which specialists should be on my child's CBAS5 care team?
A child's team commonly includes a pediatric hepatologist, metabolic or biochemical geneticist, genetic counselor, pediatric dietitian, and clinical pharmacist. These specialists coordinate liver monitoring, genetic interpretation, nutrition and vitamin support, and medication safety.
What medical records should I bring to a CBAS5 specialist visit?
A full ABCD3 genetic report, parental testing results if available, and serum or urine LC-MS reports with THCA and DHCA values are useful. Also bring chronological liver tests, growth and feeding records, and an up-to-date list of supplements with exact doses.
Can normal GGT and total bile acids rule out CBAS5?
No. GGT and total serum bile acid levels can be misleadingly normal in CBAS5, so clinicians may need to consider ABCD3 results, specialized THCA and DHCA testing, and the broader clinical picture.
How do doctors monitor whether CBAS5 treatment is working?
With bile acid replacement such as cholic acid, the team may track THCA and DHCA levels, liver tests, and the child's growth and symptoms. Regular checks of vitamins A, D, E, and K help identify problems with absorption and guide supplementation.
Why might my child need parental testing for ABCD3 variants?
If two ABCD3 variants are found in a child's report, testing both parents can show whether one variant came from each parent, a pattern called being in trans. This helps the genetics team interpret the result and discuss inheritance.
What should our CBAS5 team plan for urgent problems?
Ask whether the team has after-hours instructions for symptoms such as jaundice or bleeding and who should be contacted in an emergency. It is also reasonable to ask when referral to a liver transplant center would be considered if medical treatment is not enough.

Get notified when new evidence is published on congenital bile acid synthesis defect 5.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (13)
  1. 1

    Liver transplantation in an infant with cerebrotendinous xanthomatosis, cholestasis, and rapid evolution of liver failure.

    Pietrobattista A, Spada M, Candusso M, et al.

    Pediatric transplantation 2022; (26(6)):e14318 doi:10.1111/petr.14318.

    PMID: 35633129
  2. 2

    Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis.

    McKiernan P, Bernabeu JQ, Girard M, et al.

    JHEP reports : innovation in hepatology 2024; (6(1)):100949 doi:10.1016/j.jhepr.2023.100949.

    PMID: 38192535
  3. 3

    Oral Cholic Acid Is Efficacious and Well Tolerated in Patients With Bile Acid Synthesis and Zellweger Spectrum Disorders.

    Heubi JE, Bove KE, Setchell KDR

    Journal of pediatric gastroenterology and nutrition 2017; (65(3)):321-326 doi:10.1097/MPG.0000000000001657.

    PMID: 28644367
  4. 4

    Cholic acid for primary bile acid synthesis defects: a life-saving therapy allowing a favorable outcome in adulthood.

    Gonzales E, Matarazzo L, Franchi-Abella S, et al.

    Orphanet journal of rare diseases 2018; (13(1)):190 doi:10.1186/s13023-018-0920-5.

    PMID: 30373615
  5. 5

    Integrated genomic and biochemical diagnosis of a novel homozygous start-loss variant in AKR1D1 associated with neonatal cholestasis.

    Izquierdo-Martínez A, Rubio-Prieto JL, Rodriguez-Rodriguez A, et al.

    Clinical biochemistry 2026; (145()):111151 doi:10.1016/j.clinbiochem.2026.111151.

    PMID: 42386022
  6. 6

    [Clinical feature and genetic analysis of a family affected by congenital bile acid synthesis defect type 2: identification of 2 novel mutations in AKR1D1 gene].

    Cheng Y, Guo L, Deng M, Song YZ

    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2017; (19(7)):734-740.

    PMID: 28697823
  7. 7

    Bile Acid Synthesis Disorders in Arabs: A 10-year Screening Study.

    Al-Hussaini AA, Setchell KDR, AlSaleem B, et al.

    Journal of pediatric gastroenterology and nutrition 2017; (65(6)):613-620 doi:10.1097/MPG.0000000000001734.

    PMID: 28902093
  8. 8

    Navigating cholestasis: identifying inborn errors of bile acid metabolism for precision diagnosis.

    Nittono H, Suzuki M, Suzuki H, et al.

    Frontiers in pediatrics 2024; (12()):1385970 doi:10.3389/fped.2024.1385970.

    PMID: 38646510
  9. 9

    Congenital Bile Acid Synthesis Defect Type 2 Mimicking Biliary Atresia: A Case Report of Delta-4-3-Oxosteroid 5-Beta-Reductase Deficiency in a Two-Month-Old Infant.

    Lagrine M, Kaouani D, Elqadiry R, et al.

    Cureus 2026; (18(9)):e116257 doi:10.7759/cureus.116257.

    PMID: 42889787
  10. 10

    Expanding the genotypic spectrum of 3β-hydroxy-δ5-C27-steroid dehydrogenase (HSD3B7) deficiency: novel mutations and clinical outcomes.

    Yoldaş Çelik M, Köşeci B, Burgaç E, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2025; (38(5)):546-550 doi:10.1515/jpem-2024-0454.

    PMID: 39803807
  11. 11

    ACOX2 deficiency: An inborn error of bile acid synthesis identified in an adolescent with persistent hypertransaminasemia.

    Monte MJ, Alonso-Peña M, Briz O, et al.

    Journal of hepatology 2017; (66(3)):581-588 doi:10.1016/j.jhep.2016.11.005.

    PMID: 27884763
  12. 12

    ∆4-3-oxo-5β-reductase deficiency: favorable outcome in 16 patients treated with cholic acid.

    Gardin A, Ruiz M, Beime J, et al.

    Orphanet journal of rare diseases 2023; (18(1)):383 doi:10.1186/s13023-023-02984-z.

    PMID: 38062451
  13. 13

    Open-label Phase 3 Continuation Study of Cholic Acid in Patients With Inborn Errors of Bile Acid Synthesis.

    Heubi JE, Setchell KDR

    Journal of pediatric gastroenterology and nutrition 2020; (70(4)):423-429 doi:10.1097/MPG.0000000000002618.

    PMID: 31899729

This page is for informational purposes only and does not constitute medical advice about CBAS5. Your child's hepatologist, geneticist, and other specialists should interpret test results and make treatment decisions.